U.S. FDA Clears Abbott’s FreeStyle Libre® 2 & FreeStyle Libre® 3 Sensors For Integration With Automated Insulin Delivery Systems

Abbott announced that the U.S. Food and Drug Administration (FDA) has cleared its FreeStyle Libre 2 and FreeStyle Libre 3 integrated continuous glucose monitoring (iCGM) system sensors for integration with automated insulin delivery (AID) systems. Abbott modified the sensors to enable integration with AID systems.

AID systems help people manage daily diabetes care by automatically adjusting and administering the insulin delivered by an insulin pump based on real-time glucose data from their FreeStyle Libre 2 or FreeStyle Libre 3 sensors. The modified FreeStyle Libre 2 and FreeStyle Libre 3 sensors will be available in the U.S. later . . .